Eli Lilly (LLY) and Company announced new Phase 1 data showing that its folate receptor alpha antibody-drug conjugate (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRalpha expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate of 55% was observed at the potential recommended Phase 2 dose of 4 mg/kg. Lilly’s FRalpha targeting ADC is composed of an Fc-silent, FRalpha specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker. These data will be presented in a poster presentation at the American Society of Clinical Oncology Annual Meeting.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Nxera Pharma achieves development milestone in collaboration with Eli Lilly
- Winners and Losers: Energy Stocks Soared and Healthcare Crashed in May
- BMO Capital Markets Reiterates ‘Buy’ Rating on Eli Lilly Stock (LLY)
- Eli Lilly’s Strong Market Position and Innovative Drug Pipeline Justify Buy Rating with Target Price of USD 1,010
- Eli Lilly (LLY) Bulls Eye $1,000 Stock Price Target as GLP-1 Alpha Bandwagon Rolls On
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue